GlassScriptPhysician profile
Bina E Joseph
NPI 1346232212
$791.91
in general payments reported to CMS, 2019-2025
15 companies · $542 in 2025
The $542 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $16.44 · 2022: $39.20 · 2023: $14.67 · 2024: $39.55 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $563 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $562.55 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $189.00 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $87.31 | 2019-2025 | Tezspire, Fasenra |
| Novartis Pharmaceuticals Corporation | $83.98 | 2020-2025 | |
| Csl Behring | $80.60 | 2025 | Hizentra |
| Amgen INC. | $57.35 | 2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $47.89 | 2025 | Dupixent |
| Leo Pharma INC. | $44.94 | 2022-2025 | Anzupgo |
| Optinose US, INC. | $39.64 | 2025 | |
| Grifols USA, LLC | $38.89 | 2023-2025 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $24.95 | 2025 | Neffy |
| Lilly USA, LLC | $23.82 | 2025 | Ebglyss |
| Pfizer INC. | $20.88 | 2025 | |
| Glaxosmithkline, LLC. | $19.14 | 2024 | Nucala |
| Shire North American Group INC | $17.08 | 2019 | |
| Genentech USA, INC. | $16.44 | 2025 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bina Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.